Successful therapy of peritoneal mesothelioma with intraperitoneal chemotherapy alone. A case report.
Malignant peritoneal mesothelioma is a disease that remains relatively refractory to conventional intravenous chemotherapy with currently available agents. Single-agent and combination chemotherapy offer a response rate of 20%. Direct intraperitoneal administration of some chemotherapeutic agents results in a significant pharmacologic advantage with much greater area under the concentration versus time curve (AUC). We report a case of a patient with peritoneal mesothelioma treated with combination intraperitoneal cisplatin and Ara-C who achieved a pathologic complete remission. This patient is still alive and has been in complete remission for 53 months. This combination of intraperitoneal chemotherapy deserves further evaluation in malignant mesothelioma.
Garcia Moore
M L
ML
Section of Medical Oncology, University of Miami School of Medicine, Florida 33121.
Savaraj
N
N
Feun
L G
LG
Donnelly
E
E
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
D003561:Cytarabine; D002945:Cisplatin